{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:57:23Z","timestamp":1790618243173,"version":"4.1.0"},"reference-count":70,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00877 to Javier de las Rivas"],"award-info":[{"award-number":["PI22\/00877 to Javier de las Rivas"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","award":["anonymous philanthropic donors and institutional s"],"award-info":[{"award-number":["anonymous philanthropic donors and institutional s"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032379","name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","doi-asserted-by":"publisher","award":["FI23\/00126 to Natalia Alonso"],"award-info":[{"award-number":["FI23\/00126 to Natalia Alonso"]}],"id":[{"id":"10.13039\/100032379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal carcinoma (CRC) is frequently typified by chronic inflammation and high levels of immunosuppression that render it resistant to immunotherapy. The multimodal immunostimulatory mechanisms of oncolytic virotherapy make it an attractive strategy for priming tumors for immune-checkpoint blockade (ICB). Here, we present an emerging oncolytic virotherapeutic, rAPMV-4, with previously described efficacy in preclinical models of CRC and melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We expand on the established efficacy of APMV-4 by characterizing responses to the virotherapy in preclinical single and bilateral MicroSatellite Stable CRC tumor models. To investigate local and systemic effects of the virus, we characterized responses in tumors, draining lymph nodes, and sera using RNA-seq, high-dimensional flow cytometry, and cytokine analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>rAPMV-4 induced rapid, yet transient, interferon signaling, and early signatures of antigen presentation and T cell activation. Comparison with a human CRC cohort revealed a transcriptomic shift induced by the virus from a mesenchymal CMS4 to an \u201cimmune-high\u201d CMS1 subtype predicted to respond well to ICB. Leveraging these signatures of response and resistance to the virotherapy, we designed a rational combinatorial approach with low-dose anti-CTLA-4, which reversed Treg activation and alleviated CD4 and CD8 dysfunction, leading to more potent systemic tumor elimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This work supports the further clinical development of rAPMV-4, either alone or in combination, as an efficacious therapy for CRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015859","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:05:25Z","timestamp":1790615125000},"page":"e015859","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["In situ APMV-4 vaccination primes systemic response to subtherapeutic dosing of aCTLA-4 in colorectal carcinoma"],"prefix":"10.1136","volume":"14","author":[{"given":"Yonina","family":"Bykov","sequence":"first","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Alonso Moreda","sequence":"additional","affiliation":[{"name":"Bioinformatics and Functional Genomics Group, IBMCC, Salamanca, Spain"},{"name":"IBSAL, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Sadek","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Dawodu","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivatsan","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T","family":"Yeung","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lozano Ojalvo","sequence":"additional","affiliation":[{"name":"CIAL, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"De Las Rivas","sequence":"additional","affiliation":[{"name":"Bioinformatics and Functional Genomics Group, IBMCC, Salamanca, Spain"},{"name":"IBSAL, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Tomalka","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine, New York, New York, USA"},{"name":"Department of Medicine, Icahn School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-746X","authenticated-orcid":false,"given":"Sara","family":"Cuadrado-Castano","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine, New York, New York, USA"},{"name":"Department of Pathology, Molecular And Cell-Based Medicine, Icahn School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092810051577000_14.9.e015859.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026092810051577000_14.9.e015859.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106"},{"key":"2026092810051577000_14.9.e015859.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2021.07.004"},{"key":"2026092810051577000_14.9.e015859.4","unstructured":"Evelien D , Pieter JT , Jasper LAV , et al . Colorectal cancer. Lancet 2019;1467\u201380. Available: https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S0140673619323190?scrollTo=%23fig4"},{"key":"2026092810051577000_14.9.e015859.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.01.003"},{"key":"2026092810051577000_14.9.e015859.6","doi-asserted-by":"crossref","first-page":"118014","DOI":"10.1016\/j.biopha.2025.118014","article-title":"Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota","volume":"186","author":"Rahimi","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"2026092810051577000_14.9.e015859.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123552","article-title":"Newcastle Disease Virus at the Forefront of Cancer Immunotherapy","volume":"12","author":"Burman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026092810051577000_14.9.e015859.8","article-title":"Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment","volume":"9","author":"Bykov","year":"2023","journal-title":"J Cancer Metastasis Treat"},{"key":"2026092810051577000_14.9.e015859.9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12031098","article-title":"Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"key":"2026092810051577000_14.9.e015859.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w"},{"key":"2026092810051577000_14.9.e015859.11","article-title":"Potential disease transmission from wild geese and swans to livestock, poultry and humans: a review of the scientific literature from a One Health perspective","volume":"7","author":"Elmberg","year":"2017","journal-title":"Infect Ecol Epidemiol"},{"key":"2026092810051577000_14.9.e015859.12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.17.9522-9532.2003"},{"key":"2026092810051577000_14.9.e015859.13","first-page":"1180","article-title":"Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-\u03b3 and IL-2 from T cells","volume":"16","author":"Zhao","year":"2018","journal-title":"Oncol Lett"},{"key":"2026092810051577000_14.9.e015859.14","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J Virol"},{"key":"2026092810051577000_14.9.e015859.15","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0913"},{"key":"2026092810051577000_14.9.e015859.16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2014.02.009","article-title":"Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy","volume":"159","author":"Bai","year":"2014","journal-title":"Immunol Lett"},{"key":"2026092810051577000_14.9.e015859.17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003950","article-title":"Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3\u03b1 Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026092810051577000_14.9.e015859.18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026092810051577000_14.9.e015859.19","doi-asserted-by":"crossref","first-page":"28702","DOI":"10.18632\/oncotarget.25614","article-title":"Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus","volume":"9","author":"Oseledchyk","year":"2018","journal-title":"Oncotarget"},{"key":"2026092810051577000_14.9.e015859.20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29202"},{"key":"2026092810051577000_14.9.e015859.21","doi-asserted-by":"publisher","DOI":"10.7785\/tcrt.2012.500414"},{"key":"2026092810051577000_14.9.e015859.22","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4030016","article-title":"Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!","volume":"4","author":"Schirrmacher","year":"2016","journal-title":"Biomedicines"},{"key":"2026092810051577000_14.9.e015859.23","doi-asserted-by":"publisher","DOI":"10.1023\/B:NEON.0000021735.85511.05"},{"key":"2026092810051577000_14.9.e015859.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.08.016"},{"key":"2026092810051577000_14.9.e015859.25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ijo.2014.2692","article-title":"Strong T\u2011cell costimulation can reactivate tumor antigen\u2011specific T cells in late\u2011stage metastasized colorectal carcinoma patients: results from a phase \u2160 clinical study","volume":"46","author":"Schirrmacher","year":"2015","journal-title":"Int J Oncol"},{"key":"2026092810051577000_14.9.e015859.26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/2767-9764.CRC-22-0025","article-title":"Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models","volume":"2","author":"Javaheri","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2026092810051577000_14.9.e015859.27","doi-asserted-by":"crossref","first-page":"111717","DOI":"10.1016\/j.biopha.2021.111717","article-title":"The current understanding on the impact of KRAS on colorectal cancer","volume":"140","author":"Meng","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026092810051577000_14.9.e015859.28","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.507"},{"key":"2026092810051577000_14.9.e015859.29","first-page":"6017","article-title":"Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy","volume":"54","author":"Lorence","year":"1994","journal-title":"Cancer Res"},{"key":"2026092810051577000_14.9.e015859.30","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1099\/jgv.0.000228","article-title":"Expression of Raf kinase inhibitor protein is downregulated in response to Newcastle disease virus infection to promote viral replication","volume":"96","author":"Yin","year":"2015","journal-title":"J Gen Virol"},{"key":"2026092810051577000_14.9.e015859.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02392-x"},{"key":"2026092810051577000_14.9.e015859.32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3967"},{"key":"2026092810051577000_14.9.e015859.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-018-5193-9","article-title":"Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling","volume":"19","author":"Martinez-Romero","year":"2018","journal-title":"BMC Genomics"},{"key":"2026092810051577000_14.9.e015859.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16747-x","article-title":"CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models","volume":"7","author":"Eide","year":"2017","journal-title":"Sci Rep"},{"key":"2026092810051577000_14.9.e015859.35","doi-asserted-by":"crossref","DOI":"10.1093\/bioadv\/vbad037","article-title":"Identification of a gene expression signature associated with breast cancer survival and risk that improves clinical genomic platforms","volume":"3","author":"Bueno-Fortes","year":"2023","journal-title":"Bioinform Adv"},{"key":"2026092810051577000_14.9.e015859.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"2026092810051577000_14.9.e015859.37","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/s41588-025-02268-1","article-title":"Massively parallel immunopeptidome by DNA sequencing provides insights into cancer antigen presentation","volume":"57","author":"Shi","year":"2025","journal-title":"Nat Genet"},{"key":"2026092810051577000_14.9.e015859.38","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-025-01569-8","article-title":"PredIG: an interpretable predictor of T-cell epitope immunogenicity","volume":"17","author":"Farriol-Duran","year":"2025","journal-title":"Genome Med"},{"key":"2026092810051577000_14.9.e015859.39","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0902"},{"key":"2026092810051577000_14.9.e015859.40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98047"},{"key":"2026092810051577000_14.9.e015859.41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2501791122","article-title":"Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy","volume":"122","author":"Lugassy","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092810051577000_14.9.e015859.42","doi-asserted-by":"publisher","DOI":"10.1038\/nature15520"},{"key":"2026092810051577000_14.9.e015859.43","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8564","article-title":"Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response","volume":"8","author":"Zeng","year":"2022","journal-title":"Sci Adv"},{"key":"2026092810051577000_14.9.e015859.44","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.109"},{"key":"2026092810051577000_14.9.e015859.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06623-2"},{"key":"2026092810051577000_14.9.e015859.46","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2026092810051577000_14.9.e015859.47","article-title":"Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers","volume":"7","author":"Spiliopoulou","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"2026092810051577000_14.9.e015859.48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026092810051577000_14.9.e015859.49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343"},{"key":"2026092810051577000_14.9.e015859.50","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221166","article-title":"OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs","volume":"220","author":"Yang","year":"2023","journal-title":"J Exp Med"},{"key":"2026092810051577000_14.9.e015859.51","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-026-04396-x","article-title":"IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma","volume":"75","author":"Wu","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"2026092810051577000_14.9.e015859.52","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.83"},{"key":"2026092810051577000_14.9.e015859.53","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230053","article-title":"An oncolytic virus-delivered TGF\u03b2 inhibitor overcomes the immunosuppressive tumor microenvironment","volume":"220","author":"DePeaux","year":"2023","journal-title":"J Exp Med"},{"key":"2026092810051577000_14.9.e015859.54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.750542","article-title":"Regulatory T Cells: Regulation of Identity and Function","volume":"12","author":"Grover","year":"2021","journal-title":"Front Immunol"},{"key":"2026092810051577000_14.9.e015859.55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4086"},{"key":"2026092810051577000_14.9.e015859.56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jso.25091","article-title":"Prognostic value of intra-tumoral CD8+ \/FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis","volume":"118","author":"Sideras","year":"2018","journal-title":"J Surg Oncol"},{"key":"2026092810051577000_14.9.e015859.57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.903564","article-title":"Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting","volume":"13","author":"Aristin Revilla","year":"2022","journal-title":"Front Immunol"},{"key":"2026092810051577000_14.9.e015859.58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1022688","article-title":"The role of CXCR3 and its ligands in cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2026092810051577000_14.9.e015859.59","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636251"},{"key":"2026092810051577000_14.9.e015859.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.11.028"},{"key":"2026092810051577000_14.9.e015859.61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00110","article-title":"Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels","volume":"4","author":"Leung","year":"2014","journal-title":"Front Oncol"},{"key":"2026092810051577000_14.9.e015859.62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763877","article-title":"TGF\u03b22 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma","volume":"12","author":"Khanolkar","year":"2021","journal-title":"Front Immunol"},{"key":"2026092810051577000_14.9.e015859.63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01015"},{"key":"2026092810051577000_14.9.e015859.64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105180","article-title":"Radioimmunotherapy in colorectal cancer treatment: present and future","volume":"14","author":"Shi","year":"2023","journal-title":"Front Immunol"},{"key":"2026092810051577000_14.9.e015859.65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362224","article-title":"SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity","volume":"15","author":"Ilangumaran","year":"2024","journal-title":"Front Immunol"},{"key":"2026092810051577000_14.9.e015859.66","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.molonc.2014.03.014","article-title":"Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells","volume":"8","author":"David","year":"2014","journal-title":"Mol Oncol"},{"key":"2026092810051577000_14.9.e015859.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.028"},{"key":"2026092810051577000_14.9.e015859.68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1430136","article-title":"Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"2026092810051577000_14.9.e015859.69","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41418-019-0379-5","article-title":"RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Death Differ"},{"key":"2026092810051577000_14.9.e015859.70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1513069","article-title":"Growth arrest and DNA damage-inducible 45: a new player on inflammatory diseases","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:05:32Z","timestamp":1790615132000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015859"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015859","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}